 visitante ::
identificación
|
|||||||||||||||
|
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español | |||||||||
| Página principal > Artículos > Artículos publicados > Acute Pharmacological Effects and Oral Fluid Biomarkers of the Synthetic Cannabinoid UR-144 and THC in Recreational Users |
(Università Politecnica delle Marche (Ancona, Itàlia). Department of Excellence of Biomedical Science and Public Health) (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) (Istituto Superiore di Sanità (Roma, Itàlia). National Centre on Addiction and Doping) (Associació Benestar i Desenvolupament (Barcelona)) (Associació Benestar i Desenvolupament (Barcelona)) (Università Politecnica delle Marche (Ancona, Itàlia). Department of Excellence of Biomedical Science and Public Health) (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
| Fecha: | 2021 |
| Resumen: | UR-144 is a synthetic cannabinoid found in herbal incenses for recreational use as a substitute of cannabis. It is a cannabinoid receptor agonist with effects on the central nervous system similar to those of THC. Several cases of intoxication involving UR-144 consumption have been reported. An observational study was carried out to assess UR-144 acute pharmacological effects in comparison with cannabis measuring biomarkers of disposition in oral fluid. Both UR-144 and THC increased blood pressure and heart rate. THC induced stimulant-like and high effects significantly more than those of UR-144 and the two parent drugs could be measured in oral fluid as biomarkers of consumption within 3 h following smoking of the substance. Synthetic cannabinoids (SCs) are one of the most frequent classes of new psychoactive substances monitored by the EU Early Warning System and World Health Organization. UR-144 is a SC with a relative low affinity for the CB1 receptor with respect to that for the CB2 receptor. As with other cannabinoid receptor agonists, it has been monitored by the EU Early Warning System since 2012 for severe adverse effects on consumers. Since data for UR-144 human pharmacology are very limited, an observational study was carried out to evaluate its acute pharmacological effects following its administration using a cannabis joint as term of comparison. Disposition of UR-144 and delta-9-tetrahydrocannibinol (THC) was investigated in oral fluid. Sixteen volunteers smoked a joint prepared with tobacco and 1 or 1. 5 mg dose of UR-144 (n = 8) or cannabis flowering tops containing 10 or 20 mg THC (n = 8). Physiological variables including systolic and diastolic blood pressure, heart rate and cutaneous temperature were measured. A set of Visual Analog Scales (VAS), the Addiction Research Centre Inventory (ARCI)-49-item short form version and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) were administered to evaluate subjective effects. Oral fluid was collected at baseline, 10, 20, 40 min and 1, 2, 3 and 4 h after smoking, for UR-144 or THC concentration monitoring. Results showed significant statistical increases in both systolic and diastolic blood pressure and heart rate after both UR-144 and cannabis smoking. Both substances produced an increase in VAS related to stimulant-like and high effects, but scores were significantly higher after cannabis administration. No hallucinogenic effects were observed. Maximal oral fluid UR-144 and THC concentrations appeared at 20 and 10 min after smoking, respectively. The presence of UR-144 in oral fluid constitutes a non-invasive biomarker of SC consumption. The results of this observational study provide valuable preliminary data of the pharmacological effects of UR-144, showing a similar profile of cardiovascular effects in comparison with THC but lower intensity of subjective effects. Our results have to be confirmed by research in a larger sample to extensively clarify pharmacological effects and the health risk profile of UR-144. |
| Ayudas: | Instituto de Salud Carlos III FIS PI14/00715 Instituto de Salud Carlos III FIS PI17/01962 Instituto de Salud Carlos III FIS PI20/00879 Instituto de Salud Carlos III RD16/0017/0003 Instituto de Salud Carlos III RD16/0017/0010 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-316 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017-SGR-530 Ministerio de Sanidad, Servicios Sociales e Igualdad 2015I054 |
| Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Lengua: | Anglès |
| Documento: | Article ; recerca ; Versió publicada |
| Materia: | UR-144 ; Synthetic cannabinoids (SCs) ; Cannabis ; THC ; Physiological effects ; Subjective effects ; Oral fluid concentration |
| Publicado en: | Biology, Vol. 10 Núm. 4 (march 2021) , ISSN 2079-7737 |
